HISENSE
1.6.2021 12:00:08 CEST | Business Wire | Press release
Living under the new-normal, ESG has become one of the world's most trending topics. A positive impact on society and providing sustainable development opportunities for employees have gradually become the new criteria for companies to represent their growth. By putting talent first, Hisense strives to build a global team that includes people from different cultures and unique experiences, and to provide an equal and healthy working environment to drive its success. Together with over 90,000 employees around the world, Hisense is creating a sustainable future and exerting positive social influence constantly.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005474/en/
Focusing on local talent cultivation and cultural inclusion
Hisense supports local communities to relieve their unemployment pressure and to reduce the indirectly related crime rate. Through its investment in industrial parks worldwide, Hisense creates more than 3,000 job positions in South Africa and over 2,000 in Mexico with an expectation to expand to over 7,000 in the future, which successfully helps the local region expand its economy and boost sustainable development.
Hisense provides equal employment opportunities regardless of race and gender with professional and systematic training when recruiting local employees. For example, Nicalette, a single mother, who joined Hisense South Africa in 2002, was promoted to After-sales Manager through her excellent work performance and rapidly growing ability. Hisense’s talent employment and cultivation system has increased her passion for work and also made her life improved, according to Nicalette.
Caring for employees' career development
To empower employees, Hisense has created the necessary conditions and space for them to maximize their potential and value. Hisense implements a flexible promotion mechanism, allowing employees to choose between career paths of “management” and “R&D” for further development, which ensures a smooth promotion channel for everyone.
Hisense College, the corporate university, aims to help employees achieve better career development. A comprehensive training structure and multiple internal training platforms (including offline lecture, website, APP, etc.) are in place to help employees learn and improve anytime, anywhere.
"What makes working here different from other companies is that Hisense always motivates its employees to accomplish career goals and gives them great supports, allowing them to grow with the company." said Robin Silberbauer, who joined Hisense South Africa in 2015.
Caring for employees' health and wellbeing
During the pandemic, Hisense spares no efforts to assure employees' and their families' health through distributing epidemic prevention materials and supporting working at home.
Hisense also joins hands with professional EAP (“Employee Assistance Program”) organizations to provide mental health care for employees and their families, so that each employee can easily obtain professional psychological counselling services, which efficiently help them improve mental health and take up challenges of work and life.
Hisense will focus on talent development in the long term and actively create an inclusive workplace environment to advance the sustainable development of local communities with its global workforce.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005474/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ori Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapies15.9.2026 14:00:00 CEST | Press release
Collaboration to switch a commercial cell therapy onto the IRO® platform for an undisclosed pharma partner Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration with an undisclosed biopharmaceutical company to integrate the IRO® platform into a commercial cell therapy manufacturing process in a deal valued at up to $120M in services, milestones, equipment and consumable purchases over the next 10 years. The collaboration is designed to modernize the partner’s autologous cell therapy manufacturing infrastructure with the aim of expanding patient access to current and future potentially transformative cell therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915757436/en/ The IRO platform Autologous cell therapies, manufactured from a patient's own cells, require precise, reliable and scalable manufacturing processes. Meeting that req
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain15.9.2026 13:30:00 CEST | Press release
- Vonn shares her experience using JOURNAVX to manage her acute pain after a career-altering injury at the 2026 Winter Games - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to over one million Americans. During the 2026 Winter Games in Milano Cortina, Lindsey suffered a serious crash during her downhill race. The fall resulted in multiple injuries that required immediate surgery and several additional procedures. Now, Lindsey is sharing her story and her personal experience treating her moderate-to-severe acute pain with JOURNAVX. “I have experienced countless injuries thro
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release
Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release
The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
